Add-on effect of bedtime dosing of the α1-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy

Hypertension Research

Volumn 30, Issue 11, 2007, Pages 1097-1105

  Ikeda, Toshio ^a   Gomi, Tomoko ^a   Shibuya, Yuko ^a   Shinozaki, Shingo ^a   Suzuki, Yoshifumi ^a   Matsuda, Nami ^a  

^a Kanto Teishin Hospital   (Japan)

Author keywords

Amlodipine; Doxazosin; Insulin resistance; Left ventricular hypertrophy; Morning hypertension

Indexed keywords

AMLODIPINE; DOXAZOSIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CIRCADIAN RHYTHM; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; ECHOCARDIOGRAPHY; EDEMA; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LONG TERM CARE; MALE; MONOTHERAPY; MORNING DOSAGE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; SYSTOLIC BLOOD PRESSURE; URINE INCONTINENCE;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; AMLODIPINE; BLOOD PRESSURE; CHOLESTEROL; DOXAZOSIN; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; RECEPTORS, ADRENERGIC, ALPHA-1; TIME FACTORS; TRIGLYCERIDES;

EID: 37849006805     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.1097     Document Type: Article

References (49)

1. Muller JE: Circadian variation in cardiovascular events. Am J Hypertens 1999; 12: 35S-42S.
2. Elliot WJ: Cyclic and circadian variations in cardiovascular events. Am J Hypertens 2001; 14: 291S-295S.
3. Leary AC, Struthers AD, Donnan PT, MacDonald TM, Murphy MB: The morning surge in blood pressure and heart rate is dependent on levels of physical activity after waking. J Hypertens 2002; 20: 865-870.
4. Gosse P, Ansoborlo P, Lemetayer P, Clementy J: Left ventricular mass is better correlated with arising blood pressure than with office or occasional blood pressure. Am J Hypertens 1997; 10: 505-510.
5. Imai Y, Ohkubo T, Tsuji I, et al: Prognostic value of ambulatory and home blood pressure measurements in comparison to screening blood pressure measurements: a pilot study in Ohasama. Blood Press Monit 1996; 1: S51-S58.
6. Gosse P, Cipriano C, Bemurat L, et al: Prognostic significance of blood pressure measured on rising. J Hum Hypertens 2001; 15: 413-417.
7. Kario K, Ishikawa J, Pickering TG, et al: Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. Hypertens Res 2006; 29: 581-587.
8. Poirier L, Lefebvre J, Lacourciere Y: Chronotherapeutics: are there meaningful difference among antihypertensive drugs? Curr Hypertens Rep 1999; 1: 320-327.
9. White WB, LaRocca GM: Chronopharmacology of cardiovascular therapy. Blood Press Monit 2002; 7: 199-207.
10. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41-46.
11. Neutel JM, Smith DHG, Weber MA: Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens 2004; 17: 37-42.
12. Yamamoto Y, Sonoyama K, Matsubara K, et al: The status of hypertension management in Japan in 2000. Hypertens Res 2002; 25: 717-725.
13. Mori H, Ukai H, Yamamoto H, et al: Current status of anti-hypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143-151.
14. Chobanian AV, Bakris GL, Black HR, et al, the National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
15. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
16. World Health Organization, International Society of Hypertension Writing Group: 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-1992.
17. Williams B, Poulter NR, Brown MJ, et al: Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-185.
18. Darnis F, Poupon R: Pharmacokinetics and safety of single oral doses of amlodipine in patients with and without hepatic impairment: an open study. Int J Clin Pharm Res 1993; 13: 29-33.
19. Ishimitsu T, Minami J, Kawano Y, Numabe A, Takishita S, Matsuoka H: Amlodipine, a long-acting calcium channel blocker, attenuates morning blood pressure rise in hypertensive patients. Clin Exp Pharmacol Physiol 1999; 26: 500-504.
20. Lorimer AR, Lyons D, Fowler G, Petrie JC, Rothman MT: Differences between amlodipine and lisinopril in control of clinic and twenty-four hour ambulatory blood pressures. J Hum Hypertens 1998; 12: 411-416.
21. Ikeda T, Gomi T, Shibuya Y, et al: Morning rise in blood pressure is a predictor of left ventricular hypertrophy in treated hypertensive patients. Hypertens Res 2004; 27: 939-946.
22. White WB, Anwar YA: Evaluation of the overall efficacy of the Omron office digital blood pressure HEM-907 monitor in adults. Blood Press Monit 2001; 6: 107-110.
23. Imai Y, Otsuka K, Kawano Y, et al: Japanese Society of Hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res 2003; 26: 771-782.
24. Sahn DJ, DeMaria A, Kisslo J, Weyman A: Recommendations regarding quantitation in M-mode echocardiography: result of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
25. Devereux RB, Alonso DR, Lutas EM, et al: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
26. Reichek N, Devereux RB: Reliable estimation of peak left ventricular systolic pressure by M-mode echographic-determined end-diastolic relative wall thickness: identification of severe valvular aortic stenosis in adult patients. Am Heart J 1982; 103: 202-209.
27. Techholz LE, Kreulen T, Herman MV, Gorlin R: Problems in echocardiographic volume determinations: echocardiographic-angiographic correlation in the presence or absence of asynergy. Am J Cardiol 1976: 37; 7-11.
28. Wallerson DC, Ganau A, Roman MJ, Devereux RB: Measurement of cardiac output by M-mode and two-dimentinal echocardiography: application to patients with hypertension. Eur Heart J 1990: 11 (Suppl I); 67-78.
29. Zoghbi WA, Enriquez-Sarano M, Foster E, et al: Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16: 777-802.
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
31. Pickering TG, Levenstein M, Walmsley P, for the Hypertension and Lipid Trial Study Group: Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure: results of the HALT Study. Am J Hypertens 1994; 7: 844-847.
32. Kario K, Pickering TG, Hoshide S, et al: Morning blood pressure surge and hypertensive cerebrovascular disease. Am J Hypertens 2004; 17: 668-675.
33. Stergiou GS, Baibas NM, Gantzarou AP, et al: Reproducibility of home, ambulatory, and clinic blood pressure: implications for the design of trials for the assessment o antihypertensive drug efficacy. Am J Hypertens 2002; 15: 101-104.
34. de Champlain, Karas M, Nguyen P, et al: Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. J Hypertens 1998; 16: 1357-1369.
35. Kamoi K, Ikarashi T: The bedtime administration of doxazosin controls morning hypertension and albuminuria in patients with type-2 diabetes: evaluation using home-based blood pressure measurements. Clin Exp Hypertens 2005; 4: 369-376.
36. Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, Ma J: Impact of clinical trial results on national trends in α-blocker prescribing, 1996-2002. JAMA 2004; 291: 54-62.
37. The ALLHAT Office and Coordinators for the ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967-1975.
38. Rutter MK, Parise H, Benjamin EJ, et al: Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 2003; 107: 448-454.
39. Verdecchia P, Reboldi G, Schillaci G, et al: Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation 1999; 100: 1802-1807.
40. Andersson PE, Lithell H: Metabolic effects of doxazosin and enalapril in hypertriglycemic, hypertensive men. Am J Hypertens 1996; 9: 323-333.
41. Lender D, Arauz-Pacheco C, Breen L, Mora-Mora P, Ramirez LC, Raskin P: A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Am J Hypertens 1999; 12: 298-303.
42. de Courten M, Ferrari P, Schneider M, et al: Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. Eur J Clin Pharmacol 1993; 44: 457-462.
43. Grim RG, Flank JM, Granditis GA, et al: Long-term effects on plasma lipids on diet and drugs to treated hypertension. JAMA 1996; 275: 1549-1556.
44. Levy D, Walmsley P, Levenstein M, for the Hypertension and Lipid Trial Srusy Group: Principal results on the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. Am Heart J 1996; 131: 966-973.
45. 1-blocker, on serum lipids in hypertensive patients. Hypertnes Res 1996; 19: 43-49.
46. Marshall HG, Beevers DG: α-Adrenoceptor blocking drugs and female urinary incontinence: prevalence and reversibility. Br J Clin Pharmacol 1996; 42: 507-509.
47. Messerli FH: Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep 2002; 4: 479-482.
48. Hashimoto J, Chonan K, Aoki Y, et al: Therapeutic effects of evening administration of guanabenz and clonidine on morning hypertension: evaluation using home-based blood pressure measurements. J Hypertens 2003; 23: 805-811.
49. Gosse P, Jullien V, Jarneir P, Lametayer P, Clementy J: Echocardiographic definition of left ventricular hypertrophy in the hypertensive: which methods of indexation of left ventricular mass? J Hum Hypertens 1999; 13: 505-509.